Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
Astrid van Tubergen,
Gertjan Wolbink,
Alejandro Balsa,
Victoria Navarro-Compán,
Denis Mulleman,
John Isaac,
Meghna Jani,
Borja Hernandez-Breijo,
Johanna Elin Gehin,
Charlotte Krieckaert,
Guillaume le Mélédo
Affiliations
Astrid van Tubergen
Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
Gertjan Wolbink
Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands
Alejandro Balsa
Rheumatology, Hospital Universitario La Paz, Madrid, Spain
Victoria Navarro-Compán
Rheumatology, La Paz University Hospital, Madrid, Spain
Denis Mulleman
Department of Rheumatology, CHRU de Tours, Tours, France
John Isaac
Department of Critical Care and Anaesthesia, Queen Elizabeth Hospital Birmingham, Birmingham, UK
Meghna Jani
6Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
Borja Hernandez-Breijo
1Immuno-Rheumatology Research Group, IdiPaz, La Paz University Hospital
Johanna Elin Gehin
Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway
Charlotte Krieckaert
Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands
Guillaume le Mélédo
Department of Rheumatology, University of Tours, Tours, France